Following a diversion, a batch of heat-sensitive pharmaceutical products is considered to be in dispute and a claim is filed against the freight forwarder. The CRTL expert proceeds with a complete analysis of the file, including the cumulative temperature difference ("TOR") of the products in order to determine whether these products are likely to be reintegrated by the laboratory.
CRTL responded to a cold chain failure on a batch of therapeutic cancer vaccines. This batch suffered this incident while in the FDA approved phase 2. The CRTL expert worked with the biotech company to value the unit cost of the vaccines.